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100,000 cells, and after stimulation with LPS, it was 403 88 (n
28, adjusted to 100%). The addition of 10% irradiated human
MSCs gave 76  9%. Despite this suppression of IgG secretion,
we saw high variations in the experiments, as well as increased IgG
secretion. Stimulation with CMV gave a median of 330  98
SFU/100,000 cells (n  3), and the addition of 10% MSCs to the
culture reduced the response to 150  63. Stimulating spleen cells
with VZV gave 830 SFC/100,000 cells, which was reduced to 84
7 with 10% MSCs present. Enriched B cells were negatively
selected using immunomagnetic beads (Dynal, Norway). Using
enriched B cells, IgG production stimulated by LPS were variably
inhibited, unchanged, or stimulated after addition of 10% MSCs in
the culture, giving an average of increased IgG production (170 
53% compared with 100% in the positive control; n  5). Varia-
tions between different MSCs were similar to those using crude
spleen cells, indicating that MSCs most likely have a direct effect
on B cells, but because there might be some contaminating T cells
remaining in the culture (ﬂow cytometry showed  0.5% T cells),
we can not rule out that MSCs inhibit T cells and then in-direct
the B cells. When T cells are activated in mixed lymphocyte
cultures or by phytohemagglutinin, MSCs in high concentrations,
10% to 40% in the culture, mainly inhibit proliferation, whereas
low concentrations, 1%, in some experiments enhance lymphocyte
proliferation. For IgG secretion induced by LPS and viral antigens
CMV or VZV, 10% MSCs in culture inhibits IgG secretion in
most experiments, although a high variation in responses is seen
with this concentration. To conclude, MSCs inhibited B-cell IgG
secretion by human spleen cells induced by CMV and VZV.
However, induction by LPS on crude spleen cells or puriﬁed B
cells mainly stimulated IgG production.
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DURABLE ENGRAFTMENT OF AMD3100-MOBILIZED HEMATOPOIETIC
STEM CELLS IN A CANINE AUTOLOGOUS AND ALLOGENEIC MODEL
Burroughs, L.1,2, Mielcarek, M.1,3, Little, M.-T.1, Bridger, G.4,
MacFarland, R.4, Fricker, S.4, Sandmaier, B.1,3, Torok-Storb, B.1,
Storb, R.1,3 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2Department of Pediatrics, University of Washington, Seattle, WA;
3Department of Medicine, University of Washington, Seattle, WA;
4AnorMED, Inc., Langley, BC, Canada.
AMD3100 is a synthetic molecule that inhibits binding of stro-
mal cell–derived factor-1 to its receptor, CXCR4, expressed on
hematopoietic cells. AMD3100 treatment of animals or humans
results in mobilization of hematopoietic progenitor cells. Periph-
eral blood mononuclear cells (PBMCs) mobilized with a combina-
tion of AMD3100 plus G-CSF stably reconstituted autologous
hematopoiesis in cancer patients following myeloablative condi-
tioning. However, the engraftment potential of AMD3100-PBMC
used alone has remained unproven. We therefore studied this
potential in the autologous and DLA-identical littermate canine
hematopoietic cell transplantation (HCT) models. Pharmacoki-
netic studies performed in 4 dogs given a single dose of AMD3100
(4 mg/kg SC) demonstrated a 3- to 10-fold increase in CD34
cells measured by ﬂow cytometry, and a 2- to 5-fold increase in
CFU-GM and BFU-E within 8–10 hours of AMD3100 adminis-
tration. For autologous HCT, 4 dogs received a single dose each of
AMD3100 (4 mg/kg) followed by 3–4 hours of leukaphereses
initiated 6–7 hours after AMD3100 administration. Thereafter,
dogs were given a single dose of myeloablative total body irradia-
tion (TBI), 920 cGy at 7 cGy/min, followed by infusion of autol-
ogous AMD3100-PBMC (median CD34 cell count, 3.9 106/kg).
Neutrophil and platelet engraftment occurred at medians of 9 days
(range, 7–10 days) and 25 days (range, 23–38 days), respectively,
after HCT. At a median follow-up of 11.5 months (range, 8–12
months), all 4 dogs had normal marrow function. Because a con-
tribution of surviving endogenous stem cells to marrow function
could not be ruled out in the autologous HCT model, we next
evaluated the engraftment potential of AMD3100-PBMC in the
allogeneic HCT model. Four dogs were given AMD3100-PBMC
(median CD34 cell count, 3.4  106/kg) from DLA-identical
littermates after conditioning with 920 cGy TBI. Postgrafting
cyclosporine (5 mg/kg twice daily) was given from days1 to35.
Neutrophil and platelet engraftment occurred at medians of 9 days
(range, 8–10 days) and 26 days (range, 26–37 days), respectively.
At a median follow-up for living recipients of 162 days (range,
72–178 days), 3 dogs were alive and demonstrated 99%-100%
donor chimerism by VNTR analysis. One dog had early evidence
of engraftment but was euthanized 18 days after HCT because of
canine HSV infection and pancreatitis. In summary, both autolo-
gous and allogeneic AMD3100-PBMC transplants were associated
with timely and durable engraftment in dogs conditioned with
myeloablative TBI.
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ALLOGENEIC T CELLS INDUCE CORD BLOOD CD34 OR CD133
CELLS RAPID PROLIFERATION AND DIFFERENTIATION INTO DEN-
DRITIC CELL PRECURSORS
Abbasian, J., Mahmud, N., Rondelli, D. Section of Hematology/Oncol-
ogy, University of Illinois at Chicago, Chicago, IL.
In this study we tested whether initial contact with allogeneic
lymphocytes may increase human cord blood (CB) hemopoietic
stem cells (HSCs) alloantigen-presenting capacity. Irradiated im-
munomagnetically puriﬁed CB CD34 and CD133 HSCs in-
duced similar proliferation (mean stimulation index, 19  5 and
16 5, respectively) of allo-responders in primary mixed leukocyte
culture (MLC). Cocultures of nonirradiated CD34 or CD133
cells with irradiated allogeneic T cells for 6 days resulted in a brisk
proliferation of HSC fractions (mean stimulation index, 17  2).
HSC proliferation was inhibited by B7:CD28 blockade with
CTLA-Ig. HSC that had been cocultured with irradiated alloge-
neic T cells for 6 days, were then rechallenged as stimulators in
MLC, and induced a signiﬁcantly greater T-cell alloresponse as
compared with the same freshly isolated HSCs (stimulation index,
134 54 vs 24 8) (P .03). The phenotypic kinetics of CD34
and CD133 CB cells on contact with irradiated T cells showed a
rapid up-regulation of CD86 within 24 hours (on average from 2%
 1% to 7%  2%, and from  1% to 4%  1%, respectively).
At 3 and 6 days of culture, both CD34 and CD133 CB cells
became larger and included a population of HLADR CD14
CD86 CD11c progenitors, on average 16%, consistent with
the phenotype of DC precursors. Also, irradiated allogeneic lym-
phocytes induced the generation of 8% CD1a DCs after 8 days
of culture with HSCs. To assess the effect of allogeneic lympho-
cytes on CB CD34 cell-derived DC generation in vivo, 10
NOD/SCID mice were irradiated (300 cGy) and injected with
0.20  106 CD34 CB cells and autologous (CD34/auto) or
allogeneic (CD34/allo) MNC (ratio 1:2), or with autologous or
allogeneic cells alone as control. At 6 weeks after transplant, mar-
row cells were harvested, and human CD45 cells were on average
1.8% in CD34/auto and 3.2% in CD34/allo. Although similar
proportions of B cells (CD45CD19) and monocytes
(CD45CD14) were detected in the two groups, a greater num-
ber of myeloid dendritic cells (CD45BDCA1) was observed
in CD34/allo than in CD34/auto (0.45%  0.30% vs 0.04% 
0.04%). These ﬁndings suggest that allogeneic lymphocytes may
induce a rapid differentiation of HSC into DC with potent alloan-
tigen-presenting capacity. Future studies aimed at either selectively
abrogating this subset of progenitors or blocking HSC:T-cell re-
ciprocal activation will be developed in the attempt of facilitating
the induction of tolerance in allogeneic HSC transplantation.
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SUFFICIENT NUMBERS OF CORD BLOOD DERIVED MESENHYMAL STEM
CELLS FOR TRANSPLANTATION ARE GENERATED BY PLASTIC ADHE-
SION OR DEPLETING METHODS
Chatzistamatiou, T.K.1, Paterakis, G.2, Stavropoulos-Giokas, C.1,2,
Papassavas, A.C.1,2 1Hellenic Cord Blood Bank, Foundation for Biomed-
ical Research, Academy of Athens, Athens, Greece; 2Department of
Immunology & National Tissue Typing Center, General Hospital “G.
Gennimatas,” Athens, Greece.
Cord blood (CB) contains nonhematopoietic stem cells referred
to as mesenhymal stem cells (MSCs). These cells contained in CB
can be considered as “very young,” and thus CB may be an excel-
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lent alternative source of MSCs. The aim of this study was to
compare different enrichment methods of obtaining MSCs from
CB, to generate sufﬁcient numbers of MSCs for transplantation.
The plastic adhesion method (PAM) and the depleting method
RosetteSep (DMR) on fresh CB units were compared. Both cell
fractions were grown in Mesencult complete medium. Their pro-
liferative capacity and their phenotype during culture were tested.
The MSC phenotype was evaluated by expression of CD105,
glycophorin A, CD29, CD44, CD45, CD31, CD34, CD64,
CD62L, CD106, CD117, CD133, CD90, HLA-class I, HLA-DR,
CD1a, CD3, CD51, and CD58. Sufﬁcient numbers of cells (56.6
9.2%) were recovered after the PAM and only a few cells (5.3 
2.6%) were isolated from the whole CB using the DMR. After the
second passage, the PAM allowed 155.5  62.9% of MSCs to be
obtained, whereas 108.3  0.99% of MSCs were obtained by the
DMR. For both methods, 3 passages were needed to obtain com-
parable homogeneity, corresponding to an average of 45 days. The
CB-derived MSCs were positive for the matrix receptors CD44,
CD58, and CD105; the integrins CD29 and CD51; and the mark-
ers CD90 and HLA-class I. They were negative for the matrix
receptors CD31 and CD62L, as well as the hematopoietic markers
CD45, CD34, CD133, CD64, CD117, CD1a, CD3, and HLA-
DR. In conclusion, both methods may represent an easy way of
obtaining MSCs from CB with the aim of potential use in CB
transplantation, because MSCs facilitate and promote the overall
engraftment level of multidonor CB grafts.
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WEIGHT LOSS IN PEDIATRIC PATIENTS WITH CHRONIC GRAFT-VER-
SUS-HOST DISEASE (CGVHD)
Browning, B., Thormann, K., Tse, W., Duerst, R., Kletzel, M.,
Jacobsohn, D.A. Children’s Memorial Hospital, Northwestern Univer-
sity, Chicago, IL.
Weight loss and malnutrition are major problems in patients with
cGVHD. In adults, a low body mass index (BMI) is a predictor for
mortality; however, weight loss and BMI have not been studied in
pediatric patients with cGVHD. A retrospective study of 18 pa-
tients at Children’s Memorial Hosptial with extensive cGVHD
based on the revised Seattle Classiﬁcation was completed. Median
age at SCT was 11.5 years (range, 1–22 years); age at cGVHD
diagnosis was 12 years (range, 1–23 years). Median duration of
immunsuppressive therapy was 15.5 months (range, 3–51 months).
Maximum height, weight, and BMI change were calculated from
date of SCT through the duration of cGVHD treatment. Patients
were also graphed on standard growth charts. Patients were strat-
iﬁed into groups based on the number of organ systems involved.
Patients with multiorgan involvement had a mean maximal BMI
decrease of &minus9%, and 50% of these patients had a decrease
of 1–4 quintiles on standard weight-for-age growth charts and
remain at less than the 10th percentile in expected weight for age.
This change in BMI not only indicates a signiﬁcant decrease in
weight but also often a plateau in stature. The resolution of oral
and GI symptoms did not appear to reverse this weight loss trend,
which indicates a structural alteration in the GI tract or an in-
creased metabolic rate. All of the patients with multiorgan involve-
ment required salvage therapy beyond steroids and CSA, and 3 of
them died due to complications of cGVHD. All patients with
single organ involvement have resolved their cGVHD with stan-
dard therapy. Weight loss and malnutrition are clinically signiﬁ-
cant issues in pediatric patients with multisystem cGVHD. Weight
loss is likely another systemic manifestation of the disease and may
contribute to increased mortality in this group. Studies measuring
resting energy expenditure and intestinal permeability are under-
way to further understand the nature of weight loss in this popu-
lation.
>1 Organ Involved 1 Organ Involved P
Number of
patients
11 7
Age at HSCT 10.2 years
(5.7–14.5)
14.5 years
(11.8–17.3)
0.1
Age at cGVHD
diagnosis
10.5 years
(5.8–15)
14.7 years
(12.1–17.3)
0.14
Length of therapy 19.5 months
(10.9–28.1)
14.2 months
(12.2–16.3)
0.3
Sites of
involvement
Skin/MS 11/11 2/7 0.002
Liver 3/11 5/7 0.08
Oral 7/11 0/7 0.01
GI 2/11 0/7 0.3
Lung 1/11 0/7 0.6
Max BMI change 9% (17.6%–1.2%) 10.2% (2%–20.8%) 0.003
Max weight
change
4% (13%–5%) 14.8% (2.2%–27.4%) 0.01
Median # quintiles
dropped
1.5 (0-4) 0 (0-0) —
Weight under
25%ile
6/10 0/7 0.01
Weight under
10%ile
5/10 0/7 0.04
Deaths 3/11 0/7 0.2
Continuous variables expressed as mean with 95% CI unless where
noted. Frequencies are compared using Fisher’s exact test.
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EVALUATION OF ORAL MUCOSITIS USING A SELF-REPORTED QUES-
TIONNAIRE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES UN-
DERGOING HIGH-DOSE CHEMORADIOTHERAPY FOLLOWED BY PE-
RIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION
Stiff, P.J.1, Bensinger, W.I.2, Emmanouilides, C.3, Gentile, T.4,
Okano, G.5, Lu, J.5, Erder, M.H.6, Spielberger, R.7 1Loyola University,
Maywood, IL; 2Fred Hutchinson Cancer Research Center, Seattle, WA;
3UCLA Medical Center, Los Angeles, CA; 4SUNY Upstate Medical
University, Syracuse, NY; 5Amgen, Inc., Thousand Oaks, CA; 6Forest
Laboratories, Inc., Jersey City, NJ; 7City of Hope National Medical
Center, Duarte, CA.
Background: Oral mucositis (OM) is a frequent complication
experienced by patients with hematologic malignancies (HMs)
undergoing high-dose chemoradiotherapy (CRT) followed by pe-
ripheral blood progenitor cell transplantation (PBPCT). Patients
rate OM as the most debilitating side effect of hematologic trans-
plantation. In clinical trials, physicians assess the severity of OM
using 1 or more established clinical scales such as the WHO,
WCCNR, or RTOG. In a pivotal phase 3 randomized, placebo-
controlled, double-blind clinical trial of palifermin (a rHuKGF
molecule) in HM patients, patients assessed their OM severity and
impact on daily functions through a self-reported OM daily ques-
tionnaire (OMDQ). We compared these patient self-reporting
results with established clinical OM scales (WHO, WCCNR, and
RTOG) and report the ﬁndings here. Methods: Over a period of
40 days, patient reported mouth and throat soreness (MTS) and its
impact on swallowing, eating, drinking, talking, and sleeping
(MTS-AL) were assessed daily using the OMDQ in 212 patients
(placebo, n  106; palifermin, n  106). The mean daily compli-
ance rate for completing the self-reporting questionnaires over the
entire study period was 84% in the placebo group and 89% in the
palifermin group. The Pearson correlation coefﬁcients between
MTS/MTS-AL scores and clinical OM scales at days 7 and 14
posttransplantation and between the change in scores in MTS/
MTS-AL and clinical OM scales between days 7 and 14 posttrans-
plantation were calculated. The daily OM severity grades, as mea-
sured by OMDQ, WHO, WCCNR, and RTOG, were graphed
for comparison. Results: Patients were able to detect the increases
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